ING Groep NV Has $75.50 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

ING Groep NV lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 96.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 931,968 shares of the biopharmaceutical company's stock after buying an additional 457,847 shares during the quarter. Gilead Sciences accounts for approximately 0.6% of ING Groep NV's holdings, making the stock its 28th largest holding. ING Groep NV owned about 0.07% of Gilead Sciences worth $75,499,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Clearbridge Investments LLC lifted its stake in shares of Gilead Sciences by 179.0% in the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company's stock worth $340,526,000 after acquiring an additional 2,915,141 shares in the last quarter. abrdn plc boosted its stake in shares of Gilead Sciences by 89.0% during the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company's stock valued at $304,930,000 after buying an additional 1,772,887 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $133,584,000. AEGON ASSET MANAGEMENT UK Plc acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $63,971,000. Finally, Van ECK Associates Corp raised its holdings in Gilead Sciences by 18.3% in the third quarter. Van ECK Associates Corp now owns 4,534,839 shares of the biopharmaceutical company's stock valued at $339,841,000 after acquiring an additional 702,342 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $0.14 on Friday, hitting $67.72. The stock had a trading volume of 3,579,110 shares, compared to its average volume of 7,566,109. The company's 50-day moving average is $69.24 and its two-hundred day moving average is $74.95. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The stock has a market cap of $84.37 billion, a price-to-earnings ratio of 188.11, a P/E/G ratio of 1.37 and a beta of 0.22. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.37 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.55%. Gilead Sciences's dividend payout ratio is presently 855.56%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Maxim Group decreased their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a "buy" rating for the company in a report on Wednesday, May 1st. Cantor Fitzgerald lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set a "neutral" rating for the company in a report on Wednesday, February 7th. HSBC raised Gilead Sciences from a "reduce" rating to a "hold" rating and set a $69.00 target price on the stock in a report on Wednesday, April 24th. Oppenheimer reiterated an "outperform" rating and issued a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Finally, Mizuho reduced their price objective on Gilead Sciences from $101.00 to $90.00 and set a "buy" rating on the stock in a research note on Thursday, February 22nd. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Hold" and a consensus price target of $83.69.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares of the company's stock, valued at approximately $7,386,496.48. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.